Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Europe needs to refocus its drug anti-counterfeiting measures

This article was originally published in Scrip

Executive Summary

Counterfeit medicines have been big news in Europe over the past two months. The pharmaceutical industry, the World Health Organization and the European Parliament have been vociferously expounding on the success and progress of various initiatives aimed at preventing the emergence of fake medicinal products in the legitimate supply chain. These are welcome and laudable actions, aimed at protecting human health, but are they focusing on the right target?

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC008636

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel